NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Ms. Garrett Ingram has been appointed to its Board of Directors. Ms. Ingram joined Cipla USA, Inc. (“Cipla”) in July 2019 as Chief Commercial Officer, Specialty Hospital Business, U.S. to lead the transformation of the current and future specialty branded platforms. She will serve as one of the three Cipla representatives on Avenue’s Board of Directors, succeeding Mr. Nishant Saxena who has stepped down from Avenue’s Board of Directors to become Cipla’s Chief Executive Officer of International Business (Europe and Emerging Markets).
“Ms. Ingram’s extensive launch and commercialization expertise and proven track record of distinguished leadership will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman. “We look forward to working with her to maximize the value of IV tramadol.”
“Avenue has successfully completed its Phase 3 Program for IV tramadol, which could become an important addition in acute pain management in the U.S.,” said Ms. Ingram. “I am excited to lend my expertise to the organization to help successfully bring IV tramadol to the U.S. market.”
Garrett Ingram is a seasoned leader with more than twenty years of experience in pharmaceuticals, biotech, device strategy and marketing. Prior to her new role at Cipla, Ms. Ingram served as Chief Marketing Officer at MannKind Corporation, based in California. In addition, she has served in roles as Senior Vice President, Managed Markets at Dexcom and Vice President, Head of Market Access at Sanofi, where she had responsibility across four of the U.S. Business Units: Diabetes & Cardiovascular, General Medicines, Sanofi Genzyme Specialty Care, and Sanofi Pasteur from 2014 to 2016. Prior to joining Sanofi, she held the position of Vice President of Market Access Strategy at Bristol Myers Squibb, where she led the access, reimbursement, patient affordability and emerging customer strategy teams across the portfolio of diabetes, RA, cardiovascular, oncology, immunology, neuroscience and pipeline assets. Ms. Ingram holds a Bachelor of Science degree from East Carolina University, a Master’s Degree in public health and community education from the University of South Carolina and has completed multiple post graduate studies at Wharton School of Business.
About Avenue Therapeutics
Avenue is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue has completed its Phase 3 program of IV tramadol for the management of postoperative pain and plans to submit a New Drug Application to the U.S. Food and Drug Administration by year-end. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.avenuetx.com.
Contacts:
Jaclyn Jaffe and William Begien, Investor Relations
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
avenue.png
Source: Avenue Therapeutics
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent FBIO News
- Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/07/2024 12:30:10 PM
- Mustang Bio Announces Closing of $4 Million Public Offering • GlobeNewswire Inc. • 05/02/2024 08:01:07 PM
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer • GlobeNewswire Inc. • 05/01/2024 08:01:30 PM
- Mustang Bio Announces Pricing of $4 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 12:00:07 AM
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds • GlobeNewswire Inc. • 04/29/2024 12:00:14 PM
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 • GlobeNewswire Inc. • 04/25/2024 12:30:48 PM
- Avenue Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/24/2024 11:30:41 AM
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/28/2024 08:05:13 PM
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases • GlobeNewswire Inc. • 03/28/2024 01:00:51 PM
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:27 PM
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/18/2024 08:05:14 PM
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea • GlobeNewswire Inc. • 03/18/2024 12:30:30 PM
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 12:30:01 PM
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq • GlobeNewswire Inc. • 03/15/2024 12:15:01 PM
- Journey Medical Corporation to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/13/2024 12:30:14 PM
- Fortress Biotech to Participate in 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/12/2024 12:30:16 PM
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:30:30 PM
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:00:17 PM
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma • GlobeNewswire Inc. • 03/07/2024 12:30:12 PM
- Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease • GlobeNewswire Inc. • 03/04/2024 01:30:24 PM
- Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy • GlobeNewswire Inc. • 02/22/2024 01:30:08 PM
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/11/2024 01:30:39 PM
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference • GlobeNewswire Inc. • 01/11/2024 01:00:08 PM
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds • GlobeNewswire Inc. • 01/05/2024 02:15:43 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM